<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35565411</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2072-6694</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancers</Title>
          <ISOAbbreviation>Cancers (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hippo in Gastric Cancer: From Signalling to Therapy.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2282</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers14092282</ELocationID>
        <Abstract>
          <AbstractText>The Hippo pathway is one of the most important ones in mammals. Its key functions in cell proliferation, tissue growth, repair, and homeostasis make it the most crucial one to be controlled. Many means have been deployed for its regulation, since this pathway is not only composed of core regulatory components, but it also communicates with and regulates various other pathways, making this signalisation even more complex. Its role in cancer has been studied more and more over the past few years, and it presents YAP/TAZ as the major oncogenic actors. In this review, we relate how vital this pathway is for different organs, and how regulatory mechanisms have been bypassed to lead to cancerous states. Most studies present an upregulation status of YAP/TAZ, and urge the need to target them. A focus is made here on gastric carcinogenesis, its main dysregulations, and the major strategies adopted and tested to counteract Hippo pathway disbalance in this disease. Hippo pathway targeting can be achieved by various means, which are described in this review. Many studies have tested different potential molecules, which are detailed hereby. Though not all tested in gastric cancer, they could represent a real interest.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Seeneevassen</LastName>
            <ForeName>Lornella</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-8085-4828</Identifier>
            <AffiliationInfo>
              <Affiliation>BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dubus</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Histology and Pathology, CHU Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gronnier</LastName>
            <ForeName>Caroline</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Digestive Surgery, Haut-Lévêque Hospital, CHU Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Varon</LastName>
            <ForeName>Christine</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-4026-2016</Identifier>
            <AffiliationInfo>
              <Affiliation>BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, F-33000 Bordeaux, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancers (Basel)</MedlineTA>
        <NlmUniqueID>101526829</NlmUniqueID>
        <ISSNLinking>2072-6694</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD44</Keyword>
        <Keyword MajorTopicYN="N">LIF</Keyword>
        <Keyword MajorTopicYN="N">TAZ</Keyword>
        <Keyword MajorTopicYN="N">YAP</Keyword>
        <Keyword MajorTopicYN="N">cancer stem cells</Keyword>
        <Keyword MajorTopicYN="N">cancer therapy</Keyword>
        <Keyword MajorTopicYN="N">gastric cancer</Keyword>
        <Keyword MajorTopicYN="N">hippo</Keyword>
        <Keyword MajorTopicYN="N">verteporfin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35565411</ArticleId>
        <ArticleId IdType="pmc">PMC9105983</ArticleId>
        <ArticleId IdType="doi">10.3390/cancers14092282</ArticleId>
        <ArticleId IdType="pii">cancers14092282</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Justice R.W., Zilian O., Woods D.F., Noll M., Bryant P.J. The Drosophila Tumor Suppressor Gene Warts Encodes a Homolog of Human Myotonic Dystrophy Kinase and Is Required for the Control of Cell Shape and Proliferation. Genes Dev. 1995;9:534–546. doi: 10.1101/gad.9.5.534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.9.5.534</ArticleId>
            <ArticleId IdType="pubmed">7698644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T., Wang W., Zhang S., Stewart R.A., Yu W. Identifying Tumor Suppressors in Genetic Mosaics: The Drosophila Lats Gene Encodes a Putative Protein Kinase. Dev. Camb. Engl. 1995;121:1053–1063. doi: 10.1242/dev.121.4.1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.121.4.1053</ArticleId>
            <ArticleId IdType="pubmed">7743921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccolo S., Dupont S., Cordenonsi M. The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiol. Rev. 2014;94:1287–1312. doi: 10.1152/physrev.00005.2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00005.2014</ArticleId>
            <ArticleId IdType="pubmed">25287865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Udan R.S., Kango-Singh M., Nolo R., Tao C., Halder G. Hippo Promotes Proliferation Arrest and Apoptosis in the Salvador/Warts Pathway. Nat. Cell Biol. 2003;5:914–920. doi: 10.1038/ncb1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1050</ArticleId>
            <ArticleId IdType="pubmed">14502294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J., Wu S., Barrera J., Matthews K., Pan D. The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–434. doi: 10.1016/j.cell.2005.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2005.06.007</ArticleId>
            <ArticleId IdType="pubmed">16096061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J., Ikenoue T., Yu J., Li L., et al.  Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control. Genes Dev. 2007;21:2747–2761. doi: 10.1101/gad.1602907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1602907</ArticleId>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S. Role of YAP/TAZ in Cell-Matrix Adhesion-Mediated Signalling and Mechanotransduction. Exp. Cell Res. 2016;343:42–53. doi: 10.1016/j.yexcr.2015.10.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2015.10.034</ArticleId>
            <ArticleId IdType="pubmed">26524510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., Brummelkamp T.R. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells. Curr. Biol. 2007;17:2054–2060. doi: 10.1016/j.cub.2007.10.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2007.10.039</ArticleId>
            <ArticleId IdType="pubmed">17980593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals. Cell. 2007;130:1120–1133. doi: 10.1016/j.cell.2007.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C.-Y., Zha Z.-Y., Zhou X., Zhang H., Huang W., Zhao D., Li T., Chan S.W., Lim C.J., Hong W., et al.  The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase. J. Biol. Chem. 2010;285:37159. doi: 10.1074/jbc.M110.152942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.152942</ArticleId>
            <ArticleId IdType="pmc">PMC2988322</ArticleId>
            <ArticleId IdType="pubmed">20858893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D., Zhang Y., Wu H., Barry E., Yin Y., Lawrence E., Dawson D., Willis J.E., Markowitz S.D., Camargo F.D., et al.  Mst1 and Mst2 Protein Kinases Restrain Intestinal Stem Cell Proliferation and Colonic Tumorigenesis by Inhibition of Yes-Associated Protein (Yap) Overabundance. Proc. Natl. Acad. Sci. USA. 2011;108:E1312–E1320. doi: 10.1073/pnas.1110428108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1110428108</ArticleId>
            <ArticleId IdType="pmc">PMC3241824</ArticleId>
            <ArticleId IdType="pubmed">22042863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F., Cordenonsi M., Piccolo S. YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016;29:783–803. doi: 10.1016/j.ccell.2016.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F., Battilana G., Cordenonsi M., Piccolo S. YAP/TAZ as Therapeutic Targets in Cancer. Curr. Opin. Pharmacol. 2016;29:26–33. doi: 10.1016/j.coph.2016.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coph.2016.05.002</ArticleId>
            <ArticleId IdType="pmc">PMC6175256</ArticleId>
            <ArticleId IdType="pubmed">27262779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plouffe S.W., Meng Z., Lin K.C., Lin B., Hong A.W., Chun J.V., Guan K.-L. Characterization of Hippo Pathway Components by Gene Inactivation. Mol. Cell. 2016;64:993–1008. doi: 10.1016/j.molcel.2016.10.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2016.10.034</ArticleId>
            <ArticleId IdType="pmc">PMC5137798</ArticleId>
            <ArticleId IdType="pubmed">27912098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sudol M. Yes-Associated Protein (YAP65) Is a Proline-Rich Phosphoprotein That Binds to the SH3 Domain of the Yes Proto-Oncogene Product. Oncogene. 1994;9:2145–2152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8035999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sudol M., Chen H.I., Bougeret C., Einbond A., Bork P. Characterization of a Novel Protein-Binding Module--the WW Domain. FEBS Lett. 1995;369:67–71. doi: 10.1016/0014-5793(95)00550-S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(95)00550-S</ArticleId>
            <ArticleId IdType="pubmed">7641887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagi R., Chen L.F., Shigesada K., Murakami Y., Ito Y. A WW Domain-Containing Yes-Associated Protein (YAP) Is a Novel Transcriptional Co-Activator. EMBO J. 1999;18:2551–2562. doi: 10.1093/emboj/18.9.2551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/18.9.2551</ArticleId>
            <ArticleId IdType="pmc">PMC1171336</ArticleId>
            <ArticleId IdType="pubmed">10228168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y. Analysis of the Role of the Hippo Pathway in Cancer. J. Transl. Med. 2019;17:116. doi: 10.1186/s12967-019-1869-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-019-1869-4</ArticleId>
            <ArticleId IdType="pmc">PMC6454697</ArticleId>
            <ArticleId IdType="pubmed">30961610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Ye X., Yu J., Li L., Li W., Li S., Yu J., Lin J.D., Wang C.-Y., Chinnaiyan A.M., et al.  TEAD Mediates YAP-Dependent Gene Induction and Growth Control. Genes Dev. 2008;22:1962–1971. doi: 10.1101/gad.1664408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1664408</ArticleId>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heallen T., Morikawa Y., Leach J., Tao G., Willerson J.T., Johnson R.L., Martin J.F. Hippo Signaling Impedes Adult Heart Regeneration. Dev. Camb. Engl. 2013;140:4683–4690. doi: 10.1242/dev.102798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.102798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heallen T., Zhang M., Wang J., Bonilla-Claudio M., Klysik E., Johnson R.L., Martin J.F. Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size. Science. 2011;332:458–461. doi: 10.1126/science.1199010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1199010</ArticleId>
            <ArticleId IdType="pmc">PMC3133743</ArticleId>
            <ArticleId IdType="pubmed">21512031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin M., Kim Y., Sutherland L.B., Murakami M., Qi X., McAnally J., Porrello E.R., Mahmoud A.I., Tan W., Shelton J.M., et al.  Hippo Pathway Effector Yap Promotes Cardiac Regeneration. Proc. Natl. Acad. Sci. USA. 2013;110:13839–13844. doi: 10.1073/pnas.1313192110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1313192110</ArticleId>
            <ArticleId IdType="pmc">PMC3752208</ArticleId>
            <ArticleId IdType="pubmed">23918388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Gise A., Lin Z., Schlegelmilch K., Honor L.B., Pan G.M., Buck J.N., Ma Q., Ishiwata T., Zhou B., Camargo F.D., et al.  YAP1, the Nuclear Target of Hippo Signaling, Stimulates Heart Growth through Cardiomyocyte Proliferation but Not Hypertrophy. Proc. Natl. Acad. Sci. USA. 2012;109:2394–2399. doi: 10.1073/pnas.1116136109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1116136109</ArticleId>
            <ArticleId IdType="pmc">PMC3289361</ArticleId>
            <ArticleId IdType="pubmed">22308401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei Q.-Y., Zhang H., Zhao B., Zha Z.-Y., Bai F., Pei X.-H., Zhao S., Xiong Y., Guan K.-L. TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway. Mol. Cell. Biol. 2008;28:2426–2436. doi: 10.1128/MCB.01874-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01874-07</ArticleId>
            <ArticleId IdType="pmc">PMC2268418</ArticleId>
            <ArticleId IdType="pubmed">18227151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren F., Zhang L., Jiang J. Hippo Signaling Regulates Yorkie Nuclear Localization and Activity through 14-3-3 Dependent and Independent Mechanisms. Dev. Biol. 2010;337:303–312. doi: 10.1016/j.ydbio.2009.10.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ydbio.2009.10.046</ArticleId>
            <ArticleId IdType="pmc">PMC2812623</ArticleId>
            <ArticleId IdType="pubmed">19900439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Li L., Tumaneng K., Wang C.-Y., Guan K.-L. A Coordinated Phosphorylation by Lats and CK1 Regulates YAP Stability through SCFβ-TRCP. Genes Dev. 2010;24:72–85. doi: 10.1101/gad.1843810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1843810</ArticleId>
            <ArticleId IdType="pmc">PMC2802193</ArticleId>
            <ArticleId IdType="pubmed">20048001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zygulska A.L., Krzemieniecki K., Pierzchalski P. Hippo Pathway—Brief Overview of Its Relevance in Cancer. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2017;68:311–335.</Citation>
        </Reference>
        <Reference>
          <Citation>Oka T., Remue E., Meerschaert K., Vanloo B., Boucherie C., Gfeller D., Bader G.D., Sidhu S.S., Vandekerckhove J., Gettemans J., et al.  Functional Complexes between YAP2 and ZO-2 Are PDZ Domain-Dependent, and Regulate YAP2 Nuclear Localization and Signalling. Biochem. J. 2010;432:461–472. doi: 10.1042/BJ20100870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20100870</ArticleId>
            <ArticleId IdType="pubmed">20868367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Remue E., Meerschaert K., Oka T., Boucherie C., Vandekerckhove J., Sudol M., Gettemans J. TAZ Interacts with Zonula Occludens-1 and-2 Proteins in a PDZ-1 Dependent Manner. FEBS Lett. 2010;584:4175–4180. doi: 10.1016/j.febslet.2010.09.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2010.09.020</ArticleId>
            <ArticleId IdType="pubmed">20850437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Z., Guo H., Cao Y., Zohrabian S., Zhou P., Ma Q., VanDusen N., Guo Y., Zhang J., Stevens S.M., et al.  Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Dev. Cell. 2016;39:466–479. doi: 10.1016/j.devcel.2016.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2016.09.005</ArticleId>
            <ArticleId IdType="pmc">PMC5121000</ArticleId>
            <ArticleId IdType="pubmed">27720608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao Y., Lin S.J., Chen Y., Voon D.C.-C., Zhu F., Chuang L.S.H., Wang T., Tan P., Lee S.C., Yeoh K.G., et al.  RUNX3 Is a Novel Negative Regulator of Oncogenic TEAD–YAP Complex in Gastric Cancer. Oncogene. 2016;35:2664–2674. doi: 10.1038/onc.2015.338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.338</ArticleId>
            <ArticleId IdType="pubmed">26364597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F.-X., Zhao B., Guan K.-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163:811–828. doi: 10.1016/j.cell.2015.10.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.10.044</ArticleId>
            <ArticleId IdType="pmc">PMC4638384</ArticleId>
            <ArticleId IdType="pubmed">26544935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stokowski R.P., Cox D.R. Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease-Causing Point Mutations. Am. J. Hum. Genet. 2000;66:873–891. doi: 10.1086/302812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/302812</ArticleId>
            <ArticleId IdType="pmc">PMC1288182</ArticleId>
            <ArticleId IdType="pubmed">10712203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi C., Troutman S., Fera D., Stemmer-Rachamimov A., Avila J.L., Christian N., Persson N.L., Shimono A., Speicher D.W., Marmorstein R., et al.  A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin’s Regulation of Mitogenic Signaling and Tumor Suppressive Functions. Cancer Cell. 2011;19:527–540. doi: 10.1016/j.ccr.2011.02.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.02.017</ArticleId>
            <ArticleId IdType="pmc">PMC3075552</ArticleId>
            <ArticleId IdType="pubmed">21481793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F., Yu J., Zheng Y., Chen Q., Zhang N., Pan D. Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2. Cell. 2013;154:1342–1355. doi: 10.1016/j.cell.2013.08.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.08.025</ArticleId>
            <ArticleId IdType="pmc">PMC3835333</ArticleId>
            <ArticleId IdType="pubmed">24012335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benhamouche S., Curto M., Saotome I., Gladden A.B., Liu C.-H., Giovannini M., McClatchey A.I. Nf2/Merlin Controls Progenitor Homeostasis and Tumorigenesis in the Liver. Genes Dev. 2010;24:1718–1730. doi: 10.1101/gad.1938710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1938710</ArticleId>
            <ArticleId IdType="pmc">PMC2922501</ArticleId>
            <ArticleId IdType="pubmed">20675406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A., et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell. 2011;147:759–772. doi: 10.1016/j.cell.2011.09.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.09.048</ArticleId>
            <ArticleId IdType="pubmed">22078877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Huang J., Chen J. Angiomotin-like Proteins Associate with and Negatively Regulate YAP1. J. Biol. Chem. 2011;286:4364–4370. doi: 10.1074/jbc.C110.205401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C110.205401</ArticleId>
            <ArticleId IdType="pmc">PMC3039387</ArticleId>
            <ArticleId IdType="pubmed">21187284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Li L., Lu Q., Wang L.H., Liu C.-Y., Lei Q., Guan K.-L. Angiomotin Is a Novel Hippo Pathway Component That Inhibits YAP Oncoprotein. Genes Dev. 2011;25:51–63. doi: 10.1101/gad.2000111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.2000111</ArticleId>
            <ArticleId IdType="pmc">PMC3012936</ArticleId>
            <ArticleId IdType="pubmed">21205866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., et al.  Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation. Cell. 2011;144:782–795. doi: 10.1016/j.cell.2011.02.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.031</ArticleId>
            <ArticleId IdType="pmc">PMC3237196</ArticleId>
            <ArticleId IdType="pubmed">21376238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvis M.R., Kreger B.T., Lien W.-H., Klezovitch O., Rudakova G.M., Camargo F.D., Lantz D.M., Seykora J.T., Vasioukhin V. α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1. Sci. Signal. 2011;4:ra33. doi: 10.1126/scisignal.2001823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2001823</ArticleId>
            <ArticleId IdType="pmc">PMC3366274</ArticleId>
            <ArticleId IdType="pubmed">21610251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D., Sun Y., Wei Y., Zhang P., Rezaeian A.H., Teruya-Feldstein J., Gupta S., Liang H., Lin H.-K., Hung M.-C., et al.  LIFR Is a Breast Cancer Metastasis Suppressor Upstream of the Hippo-YAP Pathway and a Prognostic Marker. Nat. Med. 2012;18:1511–1517. doi: 10.1038/nm.2940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2940</ArticleId>
            <ArticleId IdType="pmc">PMC3684419</ArticleId>
            <ArticleId IdType="pubmed">23001183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seeneevassen L., Giraud J., Molina-Castro S., Sifré E., Tiffon C., Beauvoit C., Staedel C., Mégraud F., Lehours P., Martin O.C.B., et al.  Leukaemia Inhibitory Factor (LIF) Inhibits Cancer Stem Cells Tumorigenic Properties through Hippo Kinases Activation in Gastric Cancer. Cancers. 2020;12:2011.  doi: 10.3390/cancers12082011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12082011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai X., She P., Chi F., Feng Y., Liu H., Jin D., Zhao Y., Guo X., Jiang D., Guan K.-L., et al.  Phosphorylation of Angiomotin by Lats1/2 Kinases Inhibits F-Actin Binding, Cell Migration, and Angiogenesis. J. Biol. Chem. 2013;288:34041–34051. doi: 10.1074/jbc.M113.518019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.518019</ArticleId>
            <ArticleId IdType="pmc">PMC3837143</ArticleId>
            <ArticleId IdType="pubmed">24106267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribeiro P.S., Josué F., Wepf A., Wehr M.C., Rinner O., Kelly G., Tapon N., Gstaiger M. Combined Functional Genomic and Proteomic Approaches Identify a PP2A Complex as a Negative Regulator of Hippo Signaling. Mol. Cell. 2010;39:521–534. doi: 10.1016/j.molcel.2010.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2010.08.002</ArticleId>
            <ArticleId IdType="pubmed">20797625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiewe T., Pützer B.M. P73 in Apoptosis. Apoptosis Int. J. Program. Cell Death. 2001;6:447–452. doi: 10.1023/A:1012433522902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1012433522902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strano S., Munarriz E., Rossi M., Castagnoli L., Shaul Y., Sacchi A., Oren M., Sudol M., Cesareni G., Blandino G. Physical Interaction with Yes-Associated Protein Enhances P73 Transcriptional Activity. J. Biol. Chem. 2001;276:15164–15173. doi: 10.1074/jbc.M010484200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M010484200</ArticleId>
            <ArticleId IdType="pubmed">11278685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu S., Totty N.F., Irwin M.S., Sudol M., Downward J. Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of P73-Mediated Apoptosis. Mol. Cell. 2003;11:11–23. doi: 10.1016/S1097-2765(02)00776-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(02)00776-1</ArticleId>
            <ArticleId IdType="pubmed">12535517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danovi S.A., Rossi M., Gudmundsdottir K., Yuan M., Melino G., Basu S. Yes-Associated Protein (YAP) Is a Critical Mediator of c-Jun-Dependent Apoptosis. Cell Death Differ. 2008;15:217–219. doi: 10.1038/sj.cdd.4402226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4402226</ArticleId>
            <ArticleId IdType="pubmed">17823615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomlinson V., Gudmundsdottir K., Luong P., Leung K.-Y., Knebel A., Basu S. JNK Phosphorylates Yes-Associated Protein (YAP) to Regulate Apoptosis. Cell Death Dis. 2010;1:e29. doi: 10.1038/cddis.2010.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2010.7</ArticleId>
            <ArticleId IdType="pmc">PMC3032333</ArticleId>
            <ArticleId IdType="pubmed">21364637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy D., Adamovich Y., Reuven N., Shaul Y. Yap1 Phosphorylation by C-Abl Is a Critical Step in Selective Activation of Proapoptotic Genes in Response to DNA Damage. Mol. Cell. 2008;29:350–361. doi: 10.1016/j.molcel.2007.12.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2007.12.022</ArticleId>
            <ArticleId IdType="pubmed">18280240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L., Panciera T., Soligo S., Enzo E., Bicciato S., Dupont S., Bresolin S., Frasson C., Basso G., Guzzardo V., et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response. Cell. 2014;158:157–170. doi: 10.1016/j.cell.2014.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.06.013</ArticleId>
            <ArticleId IdType="pubmed">24976009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L., Zanconato F., Bresolin S., Forcato M., Basso G., Bicciato S., Cordenonsi M., Piccolo S. Role of TAZ as Mediator of Wnt Signaling. Cell. 2012;151:1443–1456. doi: 10.1016/j.cell.2012.11.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.11.027</ArticleId>
            <ArticleId IdType="pubmed">23245942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imajo M., Miyatake K., Iimura A., Miyamoto A., Nishida E. A Molecular Mechanism That Links Hippo Signalling to the Inhibition of Wnt/β-Catenin Signalling. EMBO J. 2012;31:1109–1122. doi: 10.1038/emboj.2011.487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emboj.2011.487</ArticleId>
            <ArticleId IdType="pmc">PMC3297994</ArticleId>
            <ArticleId IdType="pubmed">22234184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenbluh J., Nijhawan D., Cox A.G., Li X., Neal J.T., Schafer E.J., Zack T.I., Wang X., Tsherniak A., Schinzel A.C., et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. Cell. 2012;151:1457–1473. doi: 10.1016/j.cell.2012.11.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.11.026</ArticleId>
            <ArticleId IdType="pmc">PMC3530160</ArticleId>
            <ArticleId IdType="pubmed">23245941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varelas X., Miller B.W., Sopko R., Song S., Gregorieff A., Fellouse F.A., Sakuma R., Pawson T., Hunziker W., McNeill H., et al.  The Hippo Pathway Regulates Wnt/Beta-Catenin Signaling. Dev. Cell. 2010;18:579–591. doi: 10.1016/j.devcel.2010.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2010.03.007</ArticleId>
            <ArticleId IdType="pubmed">20412773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alarcón C., Zaromytidou A.-I., Xi Q., Gao S., Yu J., Fujisawa S., Barlas A., Miller A.N., Manova-Todorova K., Macias M.J., et al.  Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-Beta Pathways. Cell. 2009;139:757–769. doi: 10.1016/j.cell.2009.09.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.09.035</ArticleId>
            <ArticleId IdType="pmc">PMC2818353</ArticleId>
            <ArticleId IdType="pubmed">19914168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrigno O., Lallemand F., Verrecchia F., L’hoste S., Camonis J., Atfi A., Mauviel A. Yes-Associated Protein (YAP65) Interacts with Smad7 and Potentiates Its Inhibitory Activity against TGF-β/Smad Signaling. Oncogene. 2002;21:4879–4884. doi: 10.1038/sj.onc.1205623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1205623</ArticleId>
            <ArticleId IdType="pubmed">12118366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varelas X., Samavarchi-Tehrani P., Narimatsu M., Weiss A., Cockburn K., Larsen B.G., Rossant J., Wrana J.L. The Crumbs Complex Couples Cell Density Sensing to Hippo-Dependent Control of the TGF-β-SMAD Pathway. Dev. Cell. 2010;19:831–844. doi: 10.1016/j.devcel.2010.11.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2010.11.012</ArticleId>
            <ArticleId IdType="pubmed">21145499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M., Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L. TAZ Controls Smad Nucleocytoplasmic Shuttling and Regulates Human Embryonic Stem-Cell Self-Renewal. Nat. Cell Biol. 2008;10:837–848. doi: 10.1038/ncb1748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1748</ArticleId>
            <ArticleId IdType="pubmed">18568018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumaneng K., Schlegelmilch K., Russell R., Yimlamai D., Basnet H., Mahadevan N., Fitamant J., Bardeesy N., Camargo F., Guan K.-L. YAP Mediates Crosstalk between the Hippo and PI3K-TOR Pathways by Suppressing PTEN via MiR-29. Nat. Cell Biol. 2012;14:1322–1329. doi: 10.1038/ncb2615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2615</ArticleId>
            <ArticleId IdType="pmc">PMC4019071</ArticleId>
            <ArticleId IdType="pubmed">23143395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan W., Dai X., Dai X., Xie J., Yin S., Zhu J., Wang C., Liu Y., Guo J., Wang M., et al.  LATS Suppresses MTORC1 Activity to Directly Coordinate Hippo and MTORC1 Pathways in Growth Control. Nat. Cell Biol. 2020;22:246–256. doi: 10.1038/s41556-020-0463-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-020-0463-6</ArticleId>
            <ArticleId IdType="pmc">PMC7076906</ArticleId>
            <ArticleId IdType="pubmed">32015438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palma T.D., D’Andrea B., Liguori G., Liguoro A., Cristofaro T., de Prete D.D., Pappalardo A., Mascia A., Zannini M. TAZ Is a Coactivator for Pax8 and TTF-1, Two Transcription Factors Involved in Thyroid Differentiation. Exp. Cell Res. 2009;315:162–175. doi: 10.1016/j.yexcr.2008.10.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2008.10.016</ArticleId>
            <ArticleId IdType="pubmed">19010321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park K.-S., Whitsett J.A., Di Palma T., Hong J.-H., Yaffe M.B., Zannini M. TAZ Interacts with TTF-1 and Regulates Expression of Surfactant Protein-C. J. Biol. Chem. 2004;279:17384–17390. doi: 10.1074/jbc.M312569200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M312569200</ArticleId>
            <ArticleId IdType="pubmed">14970209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You B., Yang Y.-L., Xu Z., Dai Y., Liu S., Mao J.-H., Tetsu O., Li H., Jablons D.M., You L. Inhibition of ERK1/2 down-Regulates the Hippo/YAP Signaling Pathway in Human NSCLC Cells. Oncotarget. 2015;6:4357–4368. doi: 10.18632/oncotarget.2974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2974</ArticleId>
            <ArticleId IdType="pmc">PMC4414195</ArticleId>
            <ArticleId IdType="pubmed">25738359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu T., Sun L., Zhu X. Yes-Associated Protein Enhances Proliferation and Attenuates Sensitivity to Cisplatin in Human Gastric Cancer Cells. Biomed. Pharmacother. Biomed. Pharmacother. 2018;105:1269–1275. doi: 10.1016/j.biopha.2018.06.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.06.031</ArticleId>
            <ArticleId IdType="pubmed">30021363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRan M., Yang J., Shen C.-H., Peters E.C., Fitamant J., Chan P., Hsieh M., Zhu S., Asara J.M., Zheng B., et al.  Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-Mediated Regulation of Angiomotin-like 1 Protein. Cell Rep. 2014;9:495–503. doi: 10.1016/j.celrep.2014.09.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.09.036</ArticleId>
            <ArticleId IdType="pmc">PMC4223634</ArticleId>
            <ArticleId IdType="pubmed">25373897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann W., Mossmann D., Kleemann J., Mock K., Meisinger C., Brummer T., Herr R., Brabletz S., Stemmler M.P., Brabletz T. ZEB1 Turns into a Transcriptional Activator by Interacting with YAP1 in Aggressive Cancer Types. Nat. Commun. 2016;7:10498. doi: 10.1038/ncomms10498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10498</ArticleId>
            <ArticleId IdType="pmc">PMC4756710</ArticleId>
            <ArticleId IdType="pubmed">26876920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Xin Y., Ye F., Wang W., Lu Q., Kaplan H.J., Dean D.C. Taz-Tead1 Links Cell-Cell Contact to Zeb1 Expression, Proliferation, and Dedifferentiation in Retinal Pigment Epithelial Cells. Investig. Ophthalmol. Vis. Sci. 2010;51:3372–3378. doi: 10.1167/iovs.09-4321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.09-4321</ArticleId>
            <ArticleId IdType="pmc">PMC2904003</ArticleId>
            <ArticleId IdType="pubmed">20207963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y., Feinberg T., Keller E.T., Li X.-Y., Weiss S.J. Snail/Slug Binding Interactions with YAP/TAZ Control Skeletal Stem Cell Self-Renewal and Differentiation. Nat. Cell Biol. 2016;18:917–929. doi: 10.1038/ncb3394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3394</ArticleId>
            <ArticleId IdType="pmc">PMC5007193</ArticleId>
            <ArticleId IdType="pubmed">27479603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D., Weinberg R.A. Hallmarks of Cancer: The next Generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31–46. doi: 10.1158/2159-8290.CD-21-1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-21-1059</ArticleId>
            <ArticleId IdType="pubmed">35022204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamar J.M., Stern P., Liu H., Schindler J.W., Jiang Z.-G., Hynes R.O. The Hippo Pathway Target, YAP, Promotes Metastasis through Its TEAD-Interaction Domain. Proc. Natl. Acad. Sci. USA. 2012;109:E2441–E2450. doi: 10.1073/pnas.1212021109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1212021109</ArticleId>
            <ArticleId IdType="pmc">PMC3443162</ArticleId>
            <ArticleId IdType="pubmed">22891335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plouffe S.W., Lin K.C., Moore J.L., Tan F.E., Ma S., Ye Z., Qiu Y., Ren B., Guan K.-L. The Hippo Pathway Effector Proteins YAP and TAZ Have Both Distinct and Overlapping Functions in the Cell. J. Biol. Chem. 2018;293:11230–11240. doi: 10.1074/jbc.RA118.002715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.002715</ArticleId>
            <ArticleId IdType="pmc">PMC6052207</ArticleId>
            <ArticleId IdType="pubmed">29802201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X., Chen L., Zhou Y., Wang Q., Zheng Z., Xu B., Wu C., Zhou Q., Hu W., Wu C., et al.  A Novel Protein Encoded by a Circular RNA CircPPP1R12A Promotes Tumor Pathogenesis and Metastasis of Colon Cancer via Hippo-YAP Signaling. Mol. Cancer. 2019;18:47. doi: 10.1186/s12943-019-1010-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-1010-6</ArticleId>
            <ArticleId IdType="pmc">PMC6440158</ArticleId>
            <ArticleId IdType="pubmed">30925892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang L., Gilkes D.M., Hu H., Luo W., Bullen J.W., Liang H., Semenza G.L. HIF-1α and TAZ Serve as Reciprocal Co-Activators in Human Breast Cancer Cells. Oncotarget. 2015;6:11768–11778. doi: 10.18632/oncotarget.4190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4190</ArticleId>
            <ArticleId IdType="pmc">PMC4494903</ArticleId>
            <ArticleId IdType="pubmed">26059435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bendinelli P., Maroni P., Matteucci E., Luzzati A., Perrucchini G., Desiderio M.A. Hypoxia Inducible Factor-1 Is Activated by Transcriptional Co-Activator with PDZ-Binding Motif (TAZ) versus WWdomain-Containing Oxidoreductase (WWOX) in Hypoxic Microenvironment of Bone Metastasis from Breast Cancer. Eur. J. Cancer Oxf. Engl. 1990. 2013;49:2608–2618. doi: 10.1016/j.ejca.2013.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2013.03.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C., Wang S., Xing Z., Lin A., Liang K., Song J., Hu Q., Yao J., Chen Z., Park P.K., et al.  A ROR1-HER3-LncRNA Signalling Axis Modulates the Hippo-YAP Pathway to Regulate Bone Metastasis. Nat. Cell Biol. 2017;19:106–119. doi: 10.1038/ncb3464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3464</ArticleId>
            <ArticleId IdType="pmc">PMC5336186</ArticleId>
            <ArticleId IdType="pubmed">28114269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q., Zhang N., Gray R.S., Li H., Ewald A.J., Zahnow C.A., Pan D. A Temporal Requirement for Hippo Signaling in Mammary Gland Differentiation, Growth, and Tumorigenesis. Genes Dev. 2014;28:432–437. doi: 10.1101/gad.233676.113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.233676.113</ArticleId>
            <ArticleId IdType="pmc">PMC3950341</ArticleId>
            <ArticleId IdType="pubmed">24589775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M., Hamada K., Kawahara K., Sasaki M., Noguchi F., Chiba S., Mizuno K., Suzuki S.O., Dong Y., Tokuda M., et al.  Cancer Susceptibility and Embryonic Lethality in Mob1a/1b Double-Mutant Mice. J. Clin. Investig. 2012;122:4505–4518. doi: 10.1172/JCI63735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI63735</ArticleId>
            <ArticleId IdType="pmc">PMC3533542</ArticleId>
            <ArticleId IdType="pubmed">23143302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvo F., Ege N., Grande-Garcia A., Hooper S., Jenkins R.P., Chaudhry S.I., Harrington K., Williamson P., Moeendarbary E., Charras G., et al.  Mechanotransduction and YAP-Dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer-Associated Fibroblasts. Nat. Cell Biol. 2013;15:637–646. doi: 10.1038/ncb2756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2756</ArticleId>
            <ArticleId IdType="pmc">PMC3836234</ArticleId>
            <ArticleId IdType="pubmed">23708000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao F., Liu H., Li Z., Zhong C., Fang W. Down-Regulation of LATS2 in Non-Small Cell Lung Cancer Promoted the Growth and Motility of Cancer Cells. Tumor Biol. 2015;36:2049–2057. doi: 10.1007/s13277-014-2812-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-014-2812-1</ArticleId>
            <ArticleId IdType="pubmed">25391426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin C.-W., Chang Y.-L., Chang Y.-C., Lin J.-C., Chen C.-C., Pan S.-H., Wu C.-T., Chen H.-Y., Yang S.-C., Hong T.-M., et al.  MicroRNA-135b Promotes Lung Cancer Metastasis by Regulating Multiple Targets in the Hippo Pathway and LZTS1. Nat. Commun. 2013;4:1877. doi: 10.1038/ncomms2876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms2876</ArticleId>
            <ArticleId IdType="pubmed">23695671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurppa K.J., Liu Y., To C., Zhang T., Fan M., Vajdi A., Knelson E.H., Xie Y., Lim K., Cejas P., et al.  Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020;37:104–122. doi: 10.1016/j.ccell.2019.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.12.006</ArticleId>
            <ArticleId IdType="pmc">PMC7146079</ArticleId>
            <ArticleId IdType="pubmed">31935369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K.-P., Lee J.-H., Kim T.-S., Kim T.-H., Park H.-D., Byun J.-S., Kim M.-C., Jeong W.-I., Calvisi D.F., Kim J.-M., et al.  The Hippo-Salvador Pathway Restrains Hepatic Oval Cell Proliferation, Liver Size, and Liver Tumorigenesis. Proc. Natl. Acad. Sci. USA. 2010;107:8248–8253. doi: 10.1073/pnas.0912203107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0912203107</ArticleId>
            <ArticleId IdType="pmc">PMC2889558</ArticleId>
            <ArticleId IdType="pubmed">20404163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y., Yang C., Yang S., Cheng F., Rao J., Wang X. MiR-665 Promotes Hepatocellular Carcinoma Cell Migration, Invasion, and Proliferation by Decreasing Hippo Signaling through Targeting PTPRB. Cell Death Dis. 2018;9:954. doi: 10.1038/s41419-018-0978-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0978-y</ArticleId>
            <ArticleId IdType="pmc">PMC6148030</ArticleId>
            <ArticleId IdType="pubmed">30237408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee N.-H., Kim S.J., Hyun J. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer. Biomedicines. 2021;9:347.  doi: 10.3390/biomedicines9040347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biomedicines9040347</ArticleId>
            <ArticleId IdType="pmc">PMC8067275</ArticleId>
            <ArticleId IdType="pubmed">33808155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng L., Wang H., Han S. MiR-3910 Promotes the Growth and Migration of Cancer Cells in the Progression of Hepatocellular Carcinoma. Dig. Dis. Sci. 2017;62:2812–2820. doi: 10.1007/s10620-017-4670-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-017-4670-3</ArticleId>
            <ArticleId IdType="pubmed">28823082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi X., Zhu H.-R., Liu T.-T., Shen X.-Z., Zhu J.-M. The Hippo Pathway in Hepatocellular Carcinoma: Non-Coding RNAs in Action. Cancer Lett. 2017;400:175–182. doi: 10.1016/j.canlet.2017.04.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2017.04.032</ArticleId>
            <ArticleId IdType="pubmed">28461246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X., Yu J., Yin J., Xiang Q., Tang H., Lei X. MiR-195 Regulates Cell Apoptosis of Human Hepatocellular Carcinoma Cells by Targeting LATS2. Die Pharm. Int. J. Pharm. Sci. 2012;67:645–651.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Y., Wang X., Yang Y. Hepatic Hippo Signaling Inhibits Development of Hepatocellular Carcinoma. Clin. Mol. Hepatol. 2020;26:742–750. doi: 10.3350/cmh.2020.0178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3350/cmh.2020.0178</ArticleId>
            <ArticleId IdType="pmc">PMC7641559</ArticleId>
            <ArticleId IdType="pubmed">32981290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Ma L., Weng W., Qiao Y., Zhang Y., He J., Wang H., Xiao W., Li L., Chu Q., et al.  Mutual Interaction between YAP and CREB Promotes Tumorigenesis in Liver Cancer. Hepatology. 2013;58:1011–1020. doi: 10.1002/hep.26420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26420</ArticleId>
            <ArticleId IdType="pubmed">23532963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L., Wang J., Zhang Y., Zhang Y., Ma L., Weng W., Qiao Y., Xiao W., Wang H., Yu W., et al.  MEK1 Promotes YAP and Their Interaction Is Critical for Tumorigenesis in Liver Cancer. FEBS Lett. 2013;587:3921–3927. doi: 10.1016/j.febslet.2013.10.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2013.10.042</ArticleId>
            <ArticleId IdType="pubmed">24211253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X., Yang L., Szeto P., Abali G.K., Zhang Y., Kulkarni A., Amarasinghe K., Li J., Vergara I.A., Molania R., et al.  The Hippo Pathway Oncoprotein YAP Promotes Melanoma Cell Invasion and Spontaneous Metastasis. Oncogene. 2020;39:5267–5281. doi: 10.1038/s41388-020-1362-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-020-1362-9</ArticleId>
            <ArticleId IdType="pubmed">32561850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel H., Mathur R., Syeda S., Shrivastava A., Kumar Jha A. Promoter Hypermethylation of LATS1 Gene in Oral Squamous Cell Carcinoma (OSCC) among North Indian Population. Asian Pac. J. Cancer Prev. APJCP. 2021;22:977–982. doi: 10.31557/APJCP.2021.22.3.977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31557/APJCP.2021.22.3.977</ArticleId>
            <ArticleId IdType="pmc">PMC8286665</ArticleId>
            <ArticleId IdType="pubmed">33773564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ladiz M.A.R., Najafi M., Kordi-Tamandani D.M. Contribution of LATS1 and LATS2 Promoter Methylation in OSCC Development. J. Cell Commun. Signal. 2017;11:49–55. doi: 10.1007/s12079-016-0356-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12079-016-0356-4</ArticleId>
            <ArticleId IdType="pmc">PMC5362570</ArticleId>
            <ArticleId IdType="pubmed">27761802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao D.D., Xue W., Krall E.B., Bhutkar A., Piccioni F., Wang X., Schinzel A.C., Sood S., Rosenbluh J., Kim J.W., et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell. 2014;158:171–184. doi: 10.1016/j.cell.2014.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.06.004</ArticleId>
            <ArticleId IdType="pmc">PMC4110062</ArticleId>
            <ArticleId IdType="pubmed">24954536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Moujahed A., Brodowska K., Stryjewski T., Efstathiou N., Vasilikos I., Cichy J., Miller J., Gragoudas E., Vavvas D. Verteporfin Inhibits Growth of Human Glioma in Vitro without Light Activation. Sci. Rep. 2017;7:7602. doi: 10.1038/s41598-017-07632-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-07632-8</ArticleId>
            <ArticleId IdType="pmc">PMC5548915</ArticleId>
            <ArticleId IdType="pubmed">28790340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodowska K., Al-Moujahed A., Marmalidou A., Meyer Zu Horste M., Cichy J., Miller J., Gragoudas E., Vavvas D. The Clinically Used Photosensitizer Verteporfin (VP) Inhibits YAP-TEAD and Human Retinoblastoma Cell Growth in Vitro without Light Activation. Exp. Eye Res. 2014;124:67–73. doi: 10.1016/j.exer.2014.04.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exer.2014.04.011</ArticleId>
            <ArticleId IdType="pmc">PMC4135181</ArticleId>
            <ArticleId IdType="pubmed">24837142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasari V.R., Mazack V., Feng W., Nash J., Carey D.J., Gogoi R. Verteporfin Exhibits YAP-Independent Anti-Proliferative and Cytotoxic Effects in Endometrial Cancer Cells. Oncotarget. 2017;8:28628–28640. doi: 10.18632/oncotarget.15614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.15614</ArticleId>
            <ArticleId IdType="pmc">PMC5438678</ArticleId>
            <ArticleId IdType="pubmed">28404908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen C., Yi C. YAP/TAZ Signaling and Resistance to Cancer Therapy. Trends Cancer. 2019;5:283–296. doi: 10.1016/j.trecan.2019.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2019.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC6557283</ArticleId>
            <ArticleId IdType="pubmed">31174841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng R., Dong J. The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers. 2021;13:318.  doi: 10.3390/cancers13020318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13020318</ArticleId>
            <ArticleId IdType="pmc">PMC7830227</ArticleId>
            <ArticleId IdType="pubmed">33467099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong L., Lin F., Wu W., Liu Y., Huang W. Verteporfin Inhibits YAP-Induced Bladder Cancer Cell Growth and Invasion via Hippo Signaling Pathway. Int. J. Med. Sci. 2018;15:645–652. doi: 10.7150/ijms.23460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijms.23460</ArticleId>
            <ArticleId IdType="pmc">PMC5930467</ArticleId>
            <ArticleId IdType="pubmed">29725256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janse van Rensburg H.J., Yang X. The Roles of the Hippo Pathway in Cancer Metastasis. Cell. Signal. 2016;28:1761–1772. doi: 10.1016/j.cellsig.2016.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2016.08.004</ArticleId>
            <ArticleId IdType="pubmed">27519476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan Z., Tian Y., Niu G., Cao C. The Emerging Role of GC-MSCs in the Gastric Cancer Microenvironment: From Tumor to Tumor Immunity. Stem Cells Int. 2019;2019:8071842. doi: 10.1155/2019/8071842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/8071842</ArticleId>
            <ArticleId IdType="pmc">PMC6914970</ArticleId>
            <ArticleId IdType="pubmed">31885627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina-Castro S.E., Tiffon C., Giraud J., Boeuf H., Sifre E., Giese A., Belleannée G., Lehours P., Bessède E., Mégraud F., et al.  The Hippo Kinase LATS2 Controls Helicobacter Pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa. Cell. Mol. Gastroenterol. Hepatol. 2020;9:257–276. doi: 10.1016/j.jcmgh.2019.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmgh.2019.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC6957828</ArticleId>
            <ArticleId IdType="pubmed">31669263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiffon C., Giraud J., Molina-Castro S.E., Peru S., Seeneevassen L., Sifré E., Staedel C., Bessède E., Dubus P., Mégraud F., et al.  TAZ Controls Helicobacter Pylori-Induced Epithelial-Mesenchymal Transition and Cancer Stem Cell-Like Invasive and Tumorigenic Properties. Cells. 2020;9:1462.  doi: 10.3390/cells9061462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9061462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seeneevassen L., Bessède E., Mégraud F., Lehours P., Dubus P., Varon C. Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies. Int. J. Mol. Sci. 2021;22:3418.  doi: 10.3390/ijms22073418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22073418</ArticleId>
            <ArticleId IdType="pmc">PMC8037554</ArticleId>
            <ArticleId IdType="pubmed">33810350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varon C., Azzi-Martin L., Khalid S., Seeneevassen L., Ménard A., Spuul P. Helicobacters and Cancer, Not Only Gastric Cancer? Semin. Cancer Biol. 2021 doi: 10.1016/j.semcancer.2021.08.007. in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2021.08.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z.P., Zhu J.S., Zhang Q., Wang X.Y. A Breakdown of the Hippo Pathway in Gastric Cancer. Hepatogastroenterology. 2011;58:1611–1617. doi: 10.5754/hge10669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5754/hge10669</ArticleId>
            <ArticleId IdType="pubmed">21940329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou G.-X., Li X.-Y., Zhang Q., Zhao K., Zhang C.-P., Xue C.-H., Yang K., Tian Z.-B. Effects of the Hippo Signaling Pathway in Human Gastric Cancer. Asian Pac. J. Cancer Prev. 2013;14:5199–5205. doi: 10.7314/APJCP.2013.14.9.5199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/APJCP.2013.14.9.5199</ArticleId>
            <ArticleId IdType="pubmed">24175801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D., Li X., He Y., Li W., Wang Y., Wang H., Jiang S., Xin Y. YAP1 Enhances Cell Proliferation, Migration, and Invasion of Gastric Cancer in Vitro and in Vivo. Oncotarget. 2016;7:81062–81076. doi: 10.18632/oncotarget.13188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13188</ArticleId>
            <ArticleId IdType="pmc">PMC5348376</ArticleId>
            <ArticleId IdType="pubmed">27835600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang W., Tong J.H.M., Chan A.W.H., Lee T.-L., Lung R.W.M., Leung P.P.S., So K.K.Y., Wu K., Fan D., Yu J., et al.  Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011;17:2130–2139. doi: 10.1158/1078-0432.CCR-10-2467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2467</ArticleId>
            <ArticleId IdType="pubmed">21346147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M., Cheong J.-H., Kim H., Noh S.H., Kim H. Nuclear Expression of Yes-Associated Protein 1 Correlates with Poor Prognosis in Intestinal Type Gastric Cancer. Anticancer Res. 2012;32:3827–3834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22993325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song M., Rabkin C.S., Camargo M.C. Gastric Cancer: An Evolving Disease. Curr. Treat. Options Gastroenterol. 2018;16:561–569. doi: 10.1007/s11938-018-0203-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11938-018-0203-1</ArticleId>
            <ArticleId IdType="pmc">PMC7453722</ArticleId>
            <ArticleId IdType="pubmed">30361856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S., Wang H., Shi Z., Dong A., Zhang W., Song X., He F., Wang Y., Zhang Z., Wang W., et al.  A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. Cancer Cell. 2014;25:166–180. doi: 10.1016/j.ccr.2014.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.01.010</ArticleId>
            <ArticleId IdType="pubmed">24525233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lánczky A., Győrffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J. Med. Internet Res. 2021;23:e27633. doi: 10.2196/27633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2196/27633</ArticleId>
            <ArticleId IdType="pmc">PMC8367126</ArticleId>
            <ArticleId IdType="pubmed">34309564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective Identification of Tumorigenic Breast Cancer Cells. Proc. Natl. Acad. Sci. USA. 2003;100:3983–3988. doi: 10.1073/pnas.0530291100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0530291100</ArticleId>
            <ArticleId IdType="pmc">PMC153034</ArticleId>
            <ArticleId IdType="pubmed">12629218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Res. 2003;63:5821–5828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and Expansion of Human Colon-Cancer-Initiating Cells. Nature. 2007;445:111–115. doi: 10.1038/nature05384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05384</ArticleId>
            <ArticleId IdType="pubmed">17122771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takaishi S., Okumura T., Tu S., Wang S.S.W., Shibata W., Vigneshwaran R., Gordon S.A.K., Shimada Y., Wang T.C. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44. Stem Cells Dayt. Ohio. 2009;27:1006–1020. doi: 10.1002/stem.30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.30</ArticleId>
            <ArticleId IdType="pmc">PMC2746367</ArticleId>
            <ArticleId IdType="pubmed">19415765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda K., Saikawa Y., Ohashi M., Kumagai K., Kitajima M., Okano H., Matsuzaki Y., Kitagawa Y. Tumor Initiating Potential of Side Population Cells in Human Gastric Cancer. Int. J. Oncol. 2009;34:1201–1207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19360333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen P.H., Giraud J., Chambonnier L., Dubus P., Wittkop L., Belleannée G., Collet D., Soubeyran I., Evrard S., Rousseau B., et al.  Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. Clin. Cancer Res. 2017;23:1586–1597. doi: 10.1158/1078-0432.CCR-15-2157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2157</ArticleId>
            <ArticleId IdType="pubmed">27620279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bessède E., Staedel C., Acuña Amador L.A., Nguyen P.H., Chambonnier L., Hatakeyama M., Belleannée G., Mégraud F., Varon C. Helicobacter Pylori Generates Cells with Cancer Stem Cell Properties via Epithelial-Mesenchymal Transition-like Changes. Oncogene. 2014;33:4123–4131. doi: 10.1038/onc.2013.380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2013.380</ArticleId>
            <ArticleId IdType="pubmed">24096479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giraud J., Molina-Castro S., Seeneevassen L., Sifré E., Izotte J., Tiffon C., Staedel C., Boeuf H., Fernandez S., Barthelemy P., et al.  Verteporfin Targeting YAP1/TAZ-TEAD Transcriptional Activity Inhibits the Tumorigenic Properties of Gastric Cancer Stem Cells. Int. J. Cancer. 2019;146:2255–2267. doi: 10.1002/ijc.32667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32667</ArticleId>
            <ArticleId IdType="pubmed">31489619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimoto D., Ueda Y., Hirono Y., Goi T., Yamaguchi A. PAR1 Participates in the Ability of Multidrug Resistance and Tumorigenesis by Controlling Hippo-YAP Pathway. Oncotarget. 2015;6:34788–34799. doi: 10.18632/oncotarget.5858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5858</ArticleId>
            <ArticleId IdType="pmc">PMC4741490</ArticleId>
            <ArticleId IdType="pubmed">26431277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S., Wang Z., Li Y., Ma L., Jin J., Scott A.W., Xu Y., Estrella J.S., Song Y., Liu B., et al.  PPARδ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol. Cancer Res. 2020;18:390–402. doi: 10.1158/1541-7786.MCR-19-0895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-19-0895</ArticleId>
            <ArticleId IdType="pubmed">31796534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S., Ajani J.A., Honjo S., Maru D.M., Chen Q., Scott A.W., Heallen T.R., Xiao L., Hofstetter W.L., Weston B., et al.  Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. Cancer Res. 2014;74:4170–4182. doi: 10.1158/0008-5472.CAN-13-3569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-3569</ArticleId>
            <ArticleId IdType="pmc">PMC4136429</ArticleId>
            <ArticleId IdType="pubmed">24906622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi I.J., Kook M.-C., Kim Y.-I., Cho S.-J., Lee J.Y., Kim C.G., Park B., Nam B.-H. Helicobacter Pylori Therapy for the Prevention of Metachronous Gastric Cancer. N. Engl. J. Med. 2018;378:1085–1095. doi: 10.1056/NEJMoa1708423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1708423</ArticleId>
            <ArticleId IdType="pubmed">29562147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Wang G., Chu S.-J., Zhu J.-S., Zhang R., Lu W.-W., Xia L.-Q., Lu Y.-M., Da W., Sun Q. Loss of Large Tumor Suppressor 1 Promotes Growth and Metastasis of Gastric Cancer Cells through Upregulation of the YAP Signaling. Oncotarget. 2016;7:16180–16193. doi: 10.18632/oncotarget.7568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7568</ArticleId>
            <ArticleId IdType="pmc">PMC4941306</ArticleId>
            <ArticleId IdType="pubmed">26921249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue G., Sun X., Gimenez-Capitan A., Shen J., Yu L., Teixido C., Guan W., Rosell R., Liu B., Wei J. TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma. BioMed Res. Int. 2014;2014:393064. doi: 10.1155/2014/393064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/393064</ArticleId>
            <ArticleId IdType="pmc">PMC3953576</ArticleId>
            <ArticleId IdType="pubmed">24707483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Z., Zhou K., Wang Q., Huang Y., Ji J., Peng Y., Zhang X., Zheng T., Zhang Z., Chong D., et al.  The Transcription Factor RUNX2 Fuels YAP1 Signaling and Gastric Cancer Tumorigenesis. Cancer Sci. 2021;112:3533–3544. doi: 10.1111/cas.15045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.15045</ArticleId>
            <ArticleId IdType="pmc">PMC8409423</ArticleId>
            <ArticleId IdType="pubmed">34160112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Z.-J., Yang L., Qian F., Wang Y.-X., Yu X., Ji C.-D., Cui W., Xiang D.-F., Zhang X., Zhang P., et al.  Transcription Factor RUNX2 Up-Regulates Chemokine Receptor CXCR4 to Promote Invasive and Metastatic Potentials of Human Gastric Cancer. Oncotarget. 2016;7:20999–21012. doi: 10.18632/oncotarget.8236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8236</ArticleId>
            <ArticleId IdType="pmc">PMC4991507</ArticleId>
            <ArticleId IdType="pubmed">27007162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita T., Chiwaki F., Takahashi R., Aoyagi K., Yanagihara K., Nishimura T., Tamaoki M., Komatsu M., Komatsuzaki R., Matsusaki K., et al.  Identification and Characterization of CXCR4-Positive Gastric Cancer Stem Cells. PLoS ONE. 2015;10:e0130808.  doi: 10.1371/journal.pone.0130808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0130808</ArticleId>
            <ArticleId IdType="pmc">PMC4481351</ArticleId>
            <ArticleId IdType="pubmed">26110809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell. 2007;1:313–323. doi: 10.1016/j.stem.2007.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2007.06.002</ArticleId>
            <ArticleId IdType="pubmed">18371365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., Ratajczak J., Ratajczak M.Z. Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1–CXCR4 Axis. Stem Cells. 2005;23:879–894. doi: 10.1634/stemcells.2004-0342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/stemcells.2004-0342</ArticleId>
            <ArticleId IdType="pubmed">15888687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.-J., Kuo C., Foshag L., Bilchik A.J., Hoon D.S.B. Chemokine Receptor CXCR4 Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival. J. Clin. Oncol. 2005;23:2744–2753. doi: 10.1200/JCO.2005.07.078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.07.078</ArticleId>
            <ArticleId IdType="pubmed">15837989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., et al.  Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature. 2001;410:50–56. doi: 10.1038/35065016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35065016</ArticleId>
            <ArticleId IdType="pubmed">11242036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou W., Xian Q., Wang Q., Wu C., Yan H., Li X., Lu L., Wu C., Zhu D., Xu X., et al.  M6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the M6A Modification of YAP1. J. Oncol. 2021;2021:8875424. doi: 10.1155/2021/8875424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/8875424</ArticleId>
            <ArticleId IdType="pmc">PMC8357513</ArticleId>
            <ArticleId IdType="pubmed">34394353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y., Zhang J., Li H., Huang T., Wong C.C., Wu F., Wu M., Weng N., Liu L., Cheng A.S.L., et al.  AMOTL1 Enhances YAP1 Stability and Promotes YAP1-Driven Gastric Oncogenesis. Oncogene. 2020;39:4375–4389. doi: 10.1038/s41388-020-1293-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-020-1293-5</ArticleId>
            <ArticleId IdType="pmc">PMC7253359</ArticleId>
            <ArticleId IdType="pubmed">32313226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Wong C.C., Leung K.T., Wu F., Zhou Y., Tong J.H.M., Chan R.C.K., Li H., Wang Y., Yan H., et al.  FGF18-FGFR2 Signaling Triggers the Activation of c-Jun-YAP1 Axis to Promote Carcinogenesis in a Subgroup of Gastric Cancer Patients and Indicates Translational Potential. Oncogene. 2020;39:6647–6663. doi: 10.1038/s41388-020-01458-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-020-01458-x</ArticleId>
            <ArticleId IdType="pmc">PMC7581496</ArticleId>
            <ArticleId IdType="pubmed">32934314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y., Fang G., Guo F., Zhang H., Chen X., An L., Chen M., Zhou L., Wang W., Ye T., et al.  Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer. Cancer Cell. 2020;38:115–128.e9. doi: 10.1016/j.ccell.2020.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2020.05.019</ArticleId>
            <ArticleId IdType="pubmed">32589942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang W., Huang T., Zhou Y., Zhang J., Lung R.W.M., Tong J.H.M., Chan A.W.H., Zhang B., Wong C.C., Wu F., et al.  MiR-375 Is Involved in Hippo Pathway by Targeting YAP1/TEAD4-CTGF Axis in Gastric Carcinogenesis. Cell Death Dis. 2018;9:92. doi: 10.1038/s41419-017-0134-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-017-0134-0</ArticleId>
            <ArticleId IdType="pmc">PMC5833783</ArticleId>
            <ArticleId IdType="pubmed">29367737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belair C., Baud J., Chabas S., Sharma C.M., Vogel J., Staedel C., Darfeuille F. Helicobacter Pylori Interferes with an Embryonic Stem Cell Micro RNA Cluster to Block Cell Cycle Progression. Silence. 2011;2:7. doi: 10.1186/1758-907X-2-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-907X-2-7</ArticleId>
            <ArticleId IdType="pmc">PMC3212895</ArticleId>
            <ArticleId IdType="pubmed">22027184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Huang F., Shi Y., Zhang Q., Xu S., Yao Y., Jiang R. RP11-323N12.5 Promotes the Malignancy and Immunosuppression of Human Gastric Cancer by Increasing YAP1 Transcription. Gastric Cancer. 2020;24:85–102. doi: 10.1007/s10120-020-01099-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10120-020-01099-9</ArticleId>
            <ArticleId IdType="pubmed">32623586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K., Wang B.-J., Han W., Chi C.-H., Gu C., Wang Y., Fu X., Huang W., Liu Z., Song X. CFIm25-Regulated LncRNA Acv3UTR Promotes Gastric Tumorigenesis via MiR-590-5p/YAP1 Axis. Oncogene. 2020;39:3075–3088. doi: 10.1038/s41388-020-1213-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-020-1213-8</ArticleId>
            <ArticleId IdType="pmc">PMC7142022</ArticleId>
            <ArticleId IdType="pubmed">32066878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Di X., Bi Y., Sun S., Wang T. Long Non-Coding RNA LINC00649 Regulates YES-Associated Protein 1 (YAP1)/Hippo Pathway to Accelerate Gastric Cancer (GC) Progression via Sequestering MiR-16-5p. Bioengineered. 2021;12:1791–1802. doi: 10.1080/21655979.2021.1924554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21655979.2021.1924554</ArticleId>
            <ArticleId IdType="pmc">PMC8806528</ArticleId>
            <ArticleId IdType="pubmed">33975517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D., Wang Y., Wang H., Xin Y. The Novel Long Non-Coding RNA LATS2-AS1-001 Inhibits Gastric Cancer Progression by Regulating the LATS2/YAP1 Signaling Pathway via Binding to EZH2. Cancer Cell Int. 2020;20:204. doi: 10.1186/s12935-020-01285-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-020-01285-w</ArticleId>
            <ArticleId IdType="pmc">PMC7260745</ArticleId>
            <ArticleId IdType="pubmed">32514249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J., Zhao X., Wang K., Zhang X., Yu Y., Lv Y., Zhang S., Zhang L., Guo Y., Li Y., et al.  A Novel YAP1/SLC35B4 Regulatory Axis Contributes to Proliferation and Progression of Gastric Carcinoma. Cell Death Dis. 2019;10:452. doi: 10.1038/s41419-019-1674-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1674-2</ArticleId>
            <ArticleId IdType="pmc">PMC6555804</ArticleId>
            <ArticleId IdType="pubmed">31175271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Cao Y., Guo H., Yao Y., Li L., Chen J., Li J., Xiang X., Deng J., Xiong J. Up-Regulated Acylglycerol Kinase (AGK) Expression Associates with Gastric Cancer Progression through the Formation of a Novel YAP1-AGK-Positive Loop. J. Cell. Mol. Med. 2020;24:11133–11145. doi: 10.1111/jcmm.15613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.15613</ArticleId>
            <ArticleId IdType="pmc">PMC7576242</ArticleId>
            <ArticleId IdType="pubmed">32827244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J., Li F., Yao X., Mou T., Xu Z., Han Z., Chen S., Li W., Yu J., Qi X., et al.  The HER4-YAP1 Axis Promotes Trastuzumab Resistance in HER2-Positive Gastric Cancer by Inducing Epithelial and Mesenchymal Transition. Oncogene. 2018;37:3022–3038. doi: 10.1038/s41388-018-0204-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0204-5</ArticleId>
            <ArticleId IdType="pmc">PMC5978807</ArticleId>
            <ArticleId IdType="pubmed">29535422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge L., Li D.-S., Chen F., Feng J.-D., Li B., Wang T.-J. TAZ Overexpression Is Associated with Epithelial-Mesenchymal Transition in Cisplatin-Resistant Gastric Cancer Cells. Int. J. Oncol. 2017;51:307–315. doi: 10.3892/ijo.2017.3998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2017.3998</ArticleId>
            <ArticleId IdType="pubmed">28534974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasegawa T., Sugihara T., Hoshino Y., Tarumoto R., Matsuki Y., Kanda T., Takata T., Nagahara T., Matono T., Isomoto H. Photosensitizer Verteporfin Inhibits the Growth of YAP- and TAZ-Dominant Gastric Cancer Cells by Suppressing the Anti-Apoptotic Protein Survivin in a Light-Independent Manner. Oncol. Lett. 2021;22:703. doi: 10.3892/ol.2021.12964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2021.12964</ArticleId>
            <ArticleId IdType="pmc">PMC8358589</ArticleId>
            <ArticleId IdType="pubmed">34457058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Rao X., Cui Y., Zhang L., Li X., Wang B., Zheng Y., Teng L., Zhou T., Zhuo W. The Keratin 17/YAP/IL6 Axis Contributes to E-Cadherin Loss and Aggressiveness of Diffuse Gastric Cancer. Oncogene. 2022;41:770–781. doi: 10.1038/s41388-021-02119-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-021-02119-3</ArticleId>
            <ArticleId IdType="pubmed">34845376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito K., Liu Q., Salto-Tellez M., Yano T., Tada K., Ida H., Huang C., Shah N., Inoue M., Rajnakova A., et al.  RUNX3, a Novel Tumor Suppressor, Is Frequently Inactivated in Gastric Cancer by Protein Mislocalization. Cancer Res. 2005;65:7743–7750. doi: 10.1158/0008-5472.CAN-05-0743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-0743</ArticleId>
            <ArticleId IdType="pubmed">16140942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang J.-W., Kim M.-K., Lee Y.-S., Lee J.-W., Kim D.-M., Song S.-H., Lee J.-Y., Choi B.-Y., Min B., Chi X.-Z., et al.  RAC-LATS1/2 Signaling Regulates YAP Activity by Switching between the YAP-Binding Partners TEAD4 and RUNX3. Oncogene. 2017;36:999–1011. doi: 10.1038/onc.2016.266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.266</ArticleId>
            <ArticleId IdType="pubmed">27425596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Z., He F., Chen M., Hua L., Wang W., Jiao S., Zhou Z. DNA-Binding Mechanism of the Hippo Pathway Transcription Factor TEAD4. Oncogene. 2017;36:4362–4369. doi: 10.1038/onc.2017.24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.24</ArticleId>
            <ArticleId IdType="pubmed">28368398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Approval Package: Visudyne (Verteporfin) Injection NDA 21-119.  [(accessed on 21 January 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-119_Visudyne.cfm.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.-J., Anders R.A., Liu J.O., Pan D. Genetic and Pharmacological Disruption of the TEAD–YAP Complex Suppresses the Oncogenic Activity of YAP. Genes Dev. 2012;26:1300. doi: 10.1101/gad.192856.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.192856.112</ArticleId>
            <ArticleId IdType="pmc">PMC3387657</ArticleId>
            <ArticleId IdType="pubmed">22677547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang M.-H., Jeong G.S., Smoot D.T., Ashktorab H., Hwang C.M., Kim B.S., Kim H.S., Park Y.-Y. Verteporfin Inhibits Gastric Cancer Cell Growth by Suppressing Adhesion Molecule FAT1. Oncotarget. 2017;8:98887–98897. doi: 10.18632/oncotarget.21946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.21946</ArticleId>
            <ArticleId IdType="pmc">PMC5716775</ArticleId>
            <ArticleId IdType="pubmed">29228735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T., Zhao L., Chen S., Zheng B., Chen H., Zeng T., Sun H., Zhong S., Wu W., Lin X., et al.  The Curcumin Analogue WZ35 Affects Glycolysis Inhibition of Gastric Cancer Cells through ROS-YAP-JNK Pathway. Food Chem. Toxicol. 2020;137:111131. doi: 10.1016/j.fct.2020.111131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2020.111131</ArticleId>
            <ArticleId IdType="pubmed">31958483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Wang C., Tao Z., Zhao L., Zhu Z., Wu W., He Y., Chen H., Zheng B., Huang X., et al.  Curcumin Derivative WZ35 Inhibits Tumor Cell Growth via ROS-YAP-JNK Signaling Pathway in Breast Cancer. J. Exp. Clin. Cancer Res. 2019;38:460. doi: 10.1186/s13046-019-1424-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1424-4</ArticleId>
            <ArticleId IdType="pmc">PMC6842168</ArticleId>
            <ArticleId IdType="pubmed">31703744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng H., Wu L., Xiao H.D., Du Q., Liang J. Inhibitory Effects of Dobutamine on Human Gastric Adenocarcinoma. World J. Gastroenterol. 2014;20:17092. doi: 10.3748/wjg.v20.i45.17092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i45.17092</ArticleId>
            <ArticleId IdType="pmc">PMC4258577</ArticleId>
            <ArticleId IdType="pubmed">25493021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song J., Gao Q.-L., Wu B.-W., Zhu T., Cui X.-X., Jin C.-J., Wang S.-Y., Wang S.-H., Fu D.-J., Liu H.-M., et al.  Discovery of Tertiary Amide Derivatives Incorporating Benzothiazole Moiety as Anti-Gastric Cancer Agents in Vitro via Inhibiting Tubulin Polymerization and Activating the Hippo Signaling Pathway. Eur. J. Med. Chem. 2020;203:112618. doi: 10.1016/j.ejmech.2020.112618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2020.112618</ArticleId>
            <ArticleId IdType="pubmed">32682200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oku Y., Nishiya N., Shito T., Yamamoto R., Yamamoto Y., Oyama C., Uehara Y. Small Molecules Inhibiting the Nuclear Localization of YAP/TAZ for Chemotherapeutics and Chemosensitizers against Breast Cancers. FEBS Open Bio. 2015;5:542–549. doi: 10.1016/j.fob.2015.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fob.2015.06.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q., Xia H., Zhou S., Tang Q., Zhou J., Ren M., Bi F. Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling. OncoTargets Ther. 2020;13:2057–2066. doi: 10.2147/OTT.S237693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S237693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taccioli C., Sorrentino G., Zannini A., Caroli J., Beneventano D., Anderlucci L., Lolli M., Bicciato S., Del Sal G. MDP, a Database Linking Drug Response Data to Genomic Information, Identifies Dasatinib and Statins as a Combinatorial Strategy to Inhibit YAP/TAZ in Cancer Cells. Oncotarget. 2015;6:38854–38865. doi: 10.18632/oncotarget.5749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.5749</ArticleId>
            <ArticleId IdType="pmc">PMC4770742</ArticleId>
            <ArticleId IdType="pubmed">26513174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courtois S., Durán R.V., Giraud J., Sifré E., Izotte J., Mégraud F., Lehours P., Varon C., Bessède E. Metformin Targets Gastric Cancer Stem Cells. Eur. J. Cancer Oxf. Engl. 2017;84:193–201. doi: 10.1016/j.ejca.2017.07.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.07.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C., Zhu X., Feng W., Yu Y., Jeong K., Guo W., Lu Y., Mills G.B. Verteporfin Inhibits YAP Function through Up-Regulating 14-3-3σ Sequestering YAP in the Cytoplasm. Am. J. Cancer Res. 2015;6:27–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4759394</ArticleId>
            <ArticleId IdType="pubmed">27073720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mae Y., Kanda T., Sugihara T., Takata T., Kinoshita H., Sakaguchi T., Hasegawa T., Tarumoto R., Edano M., Kurumi H., et al.  Verteporfin-photodynamic Therapy Is Effective on Gastric Cancer Cells. Mol. Clin. Oncol. 2020;13:1. doi: 10.3892/mco.2020.2081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mco.2020.2081</ArticleId>
            <ArticleId IdType="pmc">PMC7391802</ArticleId>
            <ArticleId IdType="pubmed">32754315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z., Hu T., Xu Z., Lin Z., Zhang Z., Feng T., Zhu L., Rong Y., Shen H., Luk J.M., et al.  Targeting Hippo Pathway by Specific Interruption of YAP-TEAD Interaction Using Cyclic YAP-like Peptides. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2015;29:724–732. doi: 10.1096/fj.14-262980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.14-262980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Pan Y., Liao D., Tang J., Yao D. Peptide 17, an Inhibitor of YAP/TEAD4 Pathway, Mitigates Lung Cancer Malignancy. Trop. J. Pharm. Res. 2018;17:1255. doi: 10.4314/tjpr.v17i7.5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4314/tjpr.v17i7.5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y., Yang X., Tan J., Tian R., Shen P., Cai W., Liao H. Curcumin Suppresses the Stemness of Non-Small Cell Lung Cancer Cells via Promoting the Nuclear-Cytoplasm Translocation of TAZ. Environ. Toxicol. 2021;36:1135–1142. doi: 10.1002/tox.23112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/tox.23112</ArticleId>
            <ArticleId IdType="pubmed">33539684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H., Zhang W., Pan Y., Gao Y., Deng L., Li F., Li F., Ma X., Hou S., Xu J., et al.  YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation. Cancer Res. 2017;77:5769–5781. doi: 10.1158/0008-5472.CAN-17-0449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-0449</ArticleId>
            <ArticleId IdType="pubmed">28916653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallet B., Dupuis B., Chopin C. Dobutamine: Mechanisms of action and use in acute cardiovascular pathology. Ann. Cardiol. Angeiol. 1991;40:397–402.</Citation>
        </Reference>
        <Reference>
          <Citation>Robbers-Visser D., Luijnenburg S.E., van den Berg J., Roos-Hesselink J.W., Strengers J.L., Kapusta L., Moelker A., Helbing W.A. Safety and Observer Variability of Cardiac Magnetic Resonance Imaging Combined with Low-Dose Dobutamine Stress-Testing in Patients with Complex Congenital Heart Disease. Int. J. Cardiol. 2011;147:214–218. doi: 10.1016/j.ijcard.2009.08.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2009.08.024</ArticleId>
            <ArticleId IdType="pubmed">19740557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Approval Package: Dobutrex Solution (Dobutamine) NDA #17-820/S-037.  [(accessed on 7 February 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/17-820_Dobutrex.cfm.</Citation>
        </Reference>
        <Reference>
          <Citation>Bao Y., Nakagawa K., Yang Z., Ikeda M., Withanage K., Ishigami-Yuasa M., Okuno Y., Hata S., Nishina H., Hata Y. A Cell-Based Assay to Screen Stimulators of the Hippo Pathway Reveals the Inhibitory Effect of Dobutamine on the YAP-Dependent Gene Transcription. J. Biochem. 2011;150:199–208. doi: 10.1093/jb/mvr063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jb/mvr063</ArticleId>
            <ArticleId IdType="pubmed">21586534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Approval Package: Lescol XL (Fluvastatin Sodium) NDA #021192.  [(accessed on 23 January 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-192_Lescol.cfm.</Citation>
        </Reference>
        <Reference>
          <Citation>Drug Approval Package: Glucophage (Metformin Hydrochloride) NDA# 020357/S010.  [(accessed on 7 February 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020357s010.cfm.</Citation>
        </Reference>
        <Reference>
          <Citation>Votrient (Pazopanib) FDA Approval History—Drugs.Com.  [(accessed on 7 February 2022)].  Available online:  https://www.drugs.com/history/votrient.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Bian S.-B., Yang Y., Liang W.-Q., Zhang K.-C., Chen L., Zhang Z.-T. Leukemia Inhibitory Factor Promotes Gastric Cancer Cell Proliferation, Migration, and Invasion via the LIFR–Hippo–YAP Pathway. Ann. N. Y. Acad. Sci. 2021;1484:74–89. doi: 10.1111/nyas.14466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.14466</ArticleId>
            <ArticleId IdType="pubmed">32827446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elisi G.M., Santucci M., D’Arca D., Lauriola A., Marverti G., Losi L., Scalvini L., Bolognesi M.L., Mor M., Costi M.P. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers. 2018;10:329.  doi: 10.3390/cancers10090329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10090329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santucci M., Vignudelli T., Ferrari S., Mor M., Scalvini L., Bolognesi M.L., Uliassi E., Costi M.P. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J. Med. Chem. 2015;58:4857–4873. doi: 10.1021/jm501615v.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm501615v</ArticleId>
            <ArticleId IdType="pubmed">25719868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elbaz H.A., Stueckle T.A., Tse W., Rojanasakul Y., Dinu C.Z. Digitoxin and Its Analogs as Novel Cancer Therapeutics. Exp. Hematol. Oncol. 2012;1:4. doi: 10.1186/2162-3619-1-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2162-3619-1-4</ArticleId>
            <ArticleId IdType="pmc">PMC3506989</ArticleId>
            <ArticleId IdType="pubmed">23210930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elbaz H.A., Stueckle T.A., Wang H.-Y.L., O’Doherty G.A., Lowry D.T., Sargent L.M., Wang L., Dinu C.Z., Rojanasakul Y. Digitoxin and a Synthetic Monosaccharide Analog Inhibit Cell Viability in Lung Cancer Cells. Toxicol. Appl. Pharmacol. 2012;258:51–60. doi: 10.1016/j.taap.2011.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2011.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC3254807</ArticleId>
            <ArticleId IdType="pubmed">22037315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Lázaro M., Pastor N., Azrak S.S., Ayuso M.J., Austin C.A., Cortés F. Digitoxin Inhibits the Growth of Cancer Cell Lines at Concentrations Commonly Found in Cardiac Patients. J. Nat. Prod. 2005;68:1642–1645. doi: 10.1021/np050226l.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/np050226l</ArticleId>
            <ArticleId IdType="pubmed">16309315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., et al.  Digoxin and Other Cardiac Glycosides Inhibit HIF-1alpha Synthesis and Block Tumor Growth. Proc. Natl. Acad. Sci. USA. 2008;105:19579–19586. doi: 10.1073/pnas.0809763105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0809763105</ArticleId>
            <ArticleId IdType="pmc">PMC2604945</ArticleId>
            <ArticleId IdType="pubmed">19020076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan K.-L., Yu F., Ding S. Inhibitors of Hippo-Yap Signaling Pathway. Application Number 14406749. 2013 May 31;</Citation>
        </Reference>
        <Reference>
          <Citation>Pobbati A.V., Han X., Hung A.W., Weiguang S., Huda N., Chen G.-Y., Kang C., Chia C.S.B., Luo X., Hong W., et al.  Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Struct. Lond. Engl. 1993. 2015;23:2076–2086. doi: 10.1016/j.str.2015.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.str.2015.09.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bum-Erdene K., Zhou D., Gonzalez-Gutierrez G., Ghozayel M.K., Si Y., Xu D., Shannon H.E., Bailey B.J., Corson T.W., Pollok K.E., et al.  Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction. Cell Chem. Biol. 2019;26:378–389. doi: 10.1016/j.chembiol.2018.11.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.11.010</ArticleId>
            <ArticleId IdType="pubmed">30581134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunig V.B.K., Potowski M., Akbarzadeh M., Klika Škopić M., Dos Santos Smith D., Arendt L., Dormuth I., Adihou H., Andlovic B., Karatas H., et al.  TEAD-YAP Interaction Inhibitors and MDM2 Binders from DNA-Encoded Indole-Focused Ugi Peptidomimetics. Angew. Chem. Int. Ed. 2020;59:20338–20342. doi: 10.1002/anie.202006280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.202006280</ArticleId>
            <ArticleId IdType="pmc">PMC7689693</ArticleId>
            <ArticleId IdType="pubmed">32537835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karatas H., Akbarzadeh M., Adihou H., Hahne G., Pobbati A.V., Yihui Ng E., Guéret S.M., Sievers S., Pahl A., Metz M., et al.  Discovery of Covalent Inhibitors Targeting the Transcriptional Enhanced Associate Domain Central Pocket. J. Med. Chem. 2020;63:11972–11989. doi: 10.1021/acs.jmedchem.0c01275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.0c01275</ArticleId>
            <ArticleId IdType="pmc">PMC7586386</ArticleId>
            <ArticleId IdType="pubmed">32907324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nouri K., Azad T., Ling M., Janse van Rensburg H.J., Pipchuk A., Shen H., Hao Y., Zhang J., Yang X. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors. Cancers. 2019;11:1596.  doi: 10.3390/cancers11101596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11101596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crook Z.R., Sevilla G.P., Friend D., Brusniak M.-Y., Bandaranayake A.D., Clarke M., Gewe M., Mhyre A.J., Baker D., Strong R.K., et al.  Mammalian Display Screening of Diverse Cystine-Dense Peptides for Difficult to Drug Targets. Nat. Commun. 2017;8:2244. doi: 10.1038/s41467-017-02098-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02098-8</ArticleId>
            <ArticleId IdType="pmc">PMC5740061</ArticleId>
            <ArticleId IdType="pubmed">29269835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith S.A., Sessions R.B., Shoemark D.K., Williams C., Ebrahimighaei R., McNeill M.C., Crump M.P., McKay T.R., Harris G., Newby A.C., et al.  Antiproliferative and Antimigratory Effects of a Novel YAP–TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking. J. Med. Chem. 2019;62:1291–1305. doi: 10.1021/acs.jmedchem.8b01402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.8b01402</ArticleId>
            <ArticleId IdType="pmc">PMC6701825</ArticleId>
            <ArticleId IdType="pubmed">30640473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturbaut M., Bailly F., Coevoet M., Sileo P., Pugniere M., Liberelle M., Magnez R., Thuru X., Chartier-Harlin M.-C., Melnyk P., et al.  Discovery of a Cryptic Site at the Interface 2 of TEAD—Towards a New Family of YAP/TAZ-TEAD Inhibitors. Eur. J. Med. Chem. 2021;226:113835. doi: 10.1016/j.ejmech.2021.113835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2021.113835</ArticleId>
            <ArticleId IdType="pubmed">34509860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu W., Wang J., Li Y., Tao H., Xiong H., Lian F., Gao J., Ma H., Lu T., Zhang D., et al.  Discovery and Biological Evaluation of Vinylsulfonamide Derivatives as Highly Potent, Covalent TEAD Autopalmitoylation Inhibitors. Eur. J. Med. Chem. 2019;184:111767. doi: 10.1016/j.ejmech.2019.111767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.111767</ArticleId>
            <ArticleId IdType="pubmed">31622854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X., Sun J., Su W., Shan H., Zhang B., Wang Y., Shabanova A., Shan H., Liang H. Melatonin Protects against Lung Fibrosis by Regulating the Hippo/YAP Pathway. Int. J. Mol. Sci. 2018;19:1118.  doi: 10.3390/ijms19041118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19041118</ArticleId>
            <ArticleId IdType="pmc">PMC5979295</ArticleId>
            <ArticleId IdType="pubmed">29642520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bristol-Myers Squibb Submits New Drug Application for Dasatinib.  [(accessed on 25 April 2022)].  Available online:  https://www.drugs.com/nda/sprycel_051228.html.</Citation>
        </Reference>
        <Reference>
          <Citation>Basu D., Lettan R., Damodaran K., Strellec S., Reyes-Mugica M., Rebbaa A. Identification, Mechanism of Action and Anti-Tumor Activity of a Small Molecule Inhibitor of Hippo, TGF Beta, and WNT Signaling Pathways. Mol. Cancer Ther. 2014;13:1457–1467. doi: 10.1158/1535-7163.MCT-13-0918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0918</ArticleId>
            <ArticleId IdType="pubmed">24694946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barry E.R., Simov V., Valtingojer I., Venier O. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine. Cells. 2021;10:2715.  doi: 10.3390/cells10102715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10102715</ArticleId>
            <ArticleId IdType="pmc">PMC8534579</ArticleId>
            <ArticleId IdType="pubmed">34685695</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
